PDC31

PDC31 (also known as THG113.31) is a D-amino acid-based oligopeptide that acts as a selective prostaglandin F2α (PGF2α) receptor inhibitor. It is being developed primarily for the treatment of preterm labor and primary dysmenorrhea. Mechanistically, PDC31 inhibits the PGF2α receptor, thereby reducing the strength and duration of uterine contractions induced by prostaglandin F2α. Clinical studies have shown that intravenous infusion of PDC31 can decrease intrauterine pressure and pain associated with excessive uterine contractility in patients with primary dysmenorrhea, demonstrating dose-dependent efficacy and linear pharmacokinetics with a terminal half-life of approximately 2 hours[1][2][3][4][5]. The drug has also been shown to delay delivery in animal models of preterm labor.